Materials Design Analysis Reporting (MDAR) Checklist for Authors

The MDAR framework establishes a minimum set of requirements in transparent reporting applicable to studies in the life sciences (see Statement of Task: doi:10.31222/osf.io/9sm4x.). The MDAR checklist is a tool for authors, editors and others seeking to adopt the MDAR framework for transparent reporting in manuscripts and other outputs. Please refer to the MDAR Elaboration Document for additional context for the MDAR framework.

Materials

Antibodies	Yes (indicate where provided: section/paragraph)	n/a
Met antibody: Santa Cruz Biotechnology, sc-514148	Page 6, line 128, Materials and methods, Western blot analysis	
GAPDH antibody: Santa Cruz Biotechnology, sc-47724	Page 6, line 129, Materials and methods, Western blot analysis	
m-IgGκ BP-HRP: Santa Cruz Biotechnology, sc-516102	Page 6, line 131, Materials and methods, Western blot analysis	

Cell materials	Yes (indicate where provided: section/paragraph)	n/a
Cell lines: None	We didn't conduct cell study and cell culture in this article.	
Primary cultures: None	N/A	

Experimental animals	Yes (indicate where provided: section/paragraph)	n/a
Laboratory animals: None	We didn't conduct any animal experiment in this article.	
Animal observed in or captured from the field: None	N/A	
Model organisms: none	N/A	

Plants and microbes	Yes (indicate where provided: section/paragraph)	n/a
Plants: None	We didn't conduct any plant or microbe experiment in this article.	
Microbes: None	N/A	

Human research participants	Yes (indicate where provided: section/paragraph)	n/a
Identify authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	Ethics Committee of Central South University, No.2016-s104; Page 5, line 108, Materials and methods, Clinical Marterials	
Provide statement confirming informed consent obtained from study participants.	Page 5, line 108, Materials and methods, Clinical Marterials	
Report on age and sex for all study participants.	Page 7, line 146, Results, Clinicopathological	

Design

Study protocol	Yes (indicate where provided: section/paragraph)	n/a
For clinical trials, provide the trial registration number **OR** cite DOI in manuscript.	N/A, this article didn't describe a clinical trial	

Laboratory protocol	Yes (indicate where provided: section/paragraph)	n/a
RT-PCR and Western blot details in DOI: 10.4161/cbt.10.2.12186	Page 6, line 121, Matreials and Methods, RNA extraction and quantitative real-time RT-PCR;	

Experimental study design (statistics details)	Yes (indicate where provided: section/paragraph)	n/a
State whether and how the following have been done**, or** if they were not carried out.	This article isn't an RCT study; Page 6, line 134, Matreials and Methods, Statistical analysis;	
Sample size determination	N/A	
Randomisation	N/A	
Blinding	N/A	
Inclusion/exclusion criteria	N/A	

Sample definition and in-laboratory replication	Yes (indicate where provided: section/paragraph)	n/a
State number of times the experiment was replicated in laboratory	46 times replicated, Page 7, line 161-169, Results, Downregulation of miR-133b is closely correlated with	
Define whether data describe technical or biological replicates	Biological replicates	

Ethics	Yes (indicate where provided: section/paragraph)	n/a
Studies involving human participants: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	N/A	
Studies involving experimental animals: State details of authority granting ethics approval (IRB or equivalent committee(s), provide reference number for approval.	N/A	
Studies involving specimen and field samples: State if relevant permits obtained, provide details of authority approving study; if none were required, explain why.	Ethics Committee of Central South University, No.2016-s104; Page 5, line 108, Materials and methods, Clinical Marterials	

Dual Use Research of Concern (DURC)	Yes (indicate where provided: section/paragraph)	n/a
If study is subject to dual use research of concern, state the authority granting approval and reference number for the regulatory approval	N/A	

Analysis

Attrition	Yes (indicate where provided: section/paragraph)	n/a
State if sample or data point from the analysis is excluded, and whether the criteria for exclusion were determined and specified in advance.	N/A	

Statistics	Yes (indicate where provided: section/paragraph)	n/a
Describe statistical tests used and justify choice of tests.	Page 6, line 134, Matreials and Methods, Statistical analysis;	

Data Availability	Yes (indicate where provided: section/paragraph)	n/a
State whether newly created datasets are available, including protocols for access or restriction on access.	N/A	
If data are publicly available, provide accession number in repository or DOI or URL.	N/A	
If publicly available data are reused, provide accession number in repository or DOI or URL, where possible.	N/A	

Code Availability	Yes (indicate where provided: section/paragraph)	n/a
For all newly generated code and software essential for replicating the main findings of the study:	N/A	
State whether the code or software is available.	N/A	
If code is publicly available, provide accession number in repository, or DOI or URL.	N/A	

Reporting

Adherence to community standards	Yes (indicate where provided: section/paragraph)	n/a
MDAR framework recommends adoption of discipline-specific guidelines, established and endorsed through community initiatives. Journals have their own policy about requiring specific guidelines and recommendations to complement MDAR.	Section Acknowledgement.	
State if relevant guidelines (eg., ICMJE, MIBBI, ARRIVE) have been followed, and whether a checklist (eg., CONSORT, PRISMA, ARRIVE) is provided with the manuscript.	ICMJE guidelines were followed, as the journal follows ICMJE recommendations for publication.	

Article information: http://dx.doi.org/10.21037/tcr-20-2370.